Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

T Cell Activation By OKT3 Is a Function of the Percent Monocytes in PBMC of Healthy Donors and MDS Patients

Alison Tarke, Valentina Ferrari, BA, Hannah Fields, Luca Ferrari, Franco Ferrari, PhD, Tiffany N Tanaka, MD, Rafael Bejar, MD PhD, Antonella Vitiello, Dr. Pharm., Thomas A Lane, MD

Blood (2019) 134 (Supplement_1): 4870.

https://doi.org/10.1182/blood-2019-131474

Published: 2019

Journal Articles

A Phase 1 Clinical Trial of Personalized Adoptive Cellular Therapy Targeting Myelodysplastic Syndrome (MDS) Stem Cell Neoantigens (PACTN)

Valentina Ferrari, Tiffany N Tanaka, MD, Alison Tarke, Hanna Fields, Luca Ferrari, Alex Ni, Franco Ferrari, PhD, John Warner, PhD, Theresa Jochelson, Rafael Bejar, MD PhD, Antonella Vitiello, Dr. Pharm., Thomas A Lane, MD

Blood (2018) 132 (Supplement 1): 4373.

https://doi.org/10.1182/blood-2018-99-118834

Published: 2018

Journal Articles

The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 α (HIF-1α) activity: involvement in myeloma-induced angiogenesis

Blood (2007) 110 (13): 4464–4475.

https://doi.org/10.1182/blood-2007-02-074617

Published: 2007

Journal Articles

The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients

Nicola Giuliani, Francesca Morandi, Sara Tagliaferri, Mirca Lazzaretti, Sabrina Bonomini, Monica Crugnola, Cristina Mancini, Eugenia Martella, Luca Ferrari, Antonio Tabilio, Vittorio Rizzoli

Blood (2007) 110 (1): 334–338.

https://doi.org/10.1182/blood-2006-11-059188

Published: 2007

Journal Articles

Beta-Catenin Depended and Independent Effects Induced by Myeloma Cells in Human and Murine Osteoblasts and Osteoblast Progenitors.

Francesca Morandi, Sara Tagliaferri, Sabrina Bonomini, Mirca Lazzaretti, Luca Ferrari, Vittorio Rizzoli, Nicola Giuliani

Blood (2006) 108 (11): 3433.

https://doi.org/10.1182/blood.V108.11.3433.3433

Published: 2006

NARROW

T Cell Activation By OKT3 Is a Function of the Percent Monocytes in PBMC of Healthy Donors and MDS Patients

A Phase 1 Clinical Trial of Personalized Adoptive Cellular Therapy Targeting Myelodysplastic Syndrome (MDS) Stem Cell Neoantigens (PACTN)

The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 α (HIF-1α) activity: involvement in myeloma-induced angiogenesis

The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients

Beta-Catenin Depended and Independent Effects Induced by Myeloma Cells in Human and Murine Osteoblasts and Osteoblast Progenitors.

Email alerts

ASH Publications

American Society of Hematology

T Cell Activation By OKT3 Is a Function of the Percent Monocytes in PBMC of Healthy Donors and MDS Patients

A Phase 1 Clinical Trial of Personalized Adoptive Cellular Therapy Targeting Myelodysplastic Syndrome (MDS) Stem Cell Neoantigens (PACTN)

The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 α (HIF-1α) activity: involvement in myeloma-induced angiogenesis

The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients

Beta-Catenin Depended and Independent Effects Induced by Myeloma Cells in Human and Murine Osteoblasts and Osteoblast Progenitors.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only